ClinicalTrials.gg
CompletedNCT05968508Updated May 29, 2025

A Randomized, Double-blind, Single-dose, Two-arm Parallel Study to Compare the Pharmacokinetics and Safety of BAT1806 Prefilled Subcutaneous Injection With RoActemra® in Healthy Chinese Male Subjects

A Phase 1 interventional study of BAT1806 prefilled subcutaneous injection/RoActemra® (from EU) in Healthy Men, sponsored by Bio-Thera Solutions. Completed at 1 site in China. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by Bio-Thera Solutions · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a randomized, double-blind, single-dose, two-arm parallel study to compare the pharmacokinetics, safety and immunogenicity of BAT1806 prefilled subcutaneous injection with RoActemra® (from EU) in healthy male subjects.

Read the detailed description

A total of 150 subjects are planned to be enrolled and 1:1randomized to receive single dose of 162 mg/0.9 mL BAT1806 injection, or RoActemra® (from EU) subcutaneously.

A 14-day screening period is set in this study. Subjects will be admitted one day prior to administration (Day -1) and can be discharged only upon completion of relevant observations and evaluations after administration on Day 5. After discharge, subjects need to return to the hospital for 10 follow-ups as required in the study.

02

Conditions studied

  • Healthy Men
03

In context

Lead sponsor

Bio-Thera Solutions is the lead sponsor of 57 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects can be enrolled only when they meet all the following inclusion criteria:

    1. Signed the form prior to the study, sufficient understanding of the content, procedure and possible adverse reactions of the study;
    2. Willing and able to comply with the visit and treatment specified in the study;
    3. Subjects (including their partners) who are willing to refrain from pregnancy, sperm donation and take effective method in the future 6 months (i.e., 6 months after study medication), see Appendix 4 for the detailed contraceptive measures;
    4. Healthy male subjects aged 18~55 years (inclusive);
    5. ranging from 18.0~28.0 kg/m2 (inclusive), and weight ranging from 55.0~85.0 kg (inclusive);
    6. Normal or abnormal physical examination that is judged as clinically insignificant;

Exclusion criteria

Exclusion Criteria:

  • Subjects can not be enrolled in this study if any of the following criteria is met:

    1. Smoking >5 cigarettes per day within three months prior to the study;
    2. Any serious allergic reaction to food or drug at present or in the past, or allergy to Tocilizumab, or serious allergy or allergic reaction to human, humanized or murine monoclonal antibody;
    3. History of excessive drinking (14 units of alcohol per week: 1 unit = 285 mL beer, or 25 mL liquor, or 125 mL wine);
    4. Blood donation or massive blood loss (>450 mL) within three months prior to screening, or plan for blood donation or surgery during the study;
    5. Intake of any prescription drug, over-the-counter drug, any vitamin product or herbal medicine within 28 days prior to screening;
    6. Great change in dietary or exercise habit within 2 weeks prior to screening or from screening to administration;
    7. Having any disease that may increase hemorrhagic risk, such as haemorrhoids with hemorrhagic symptoms, acute gastritis or gastric and duodenal ulcer;
    8. abnormality in echocardiography;
    9. Clinically significant abnormality in clinical laboratory examination, or other clinical findings showing the following disorders of clinical relevance (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immune, mental or cerebro- and cardiovascular diseases);
    10. Clinically significant (judged by investigators) abnormality in , or > 450ms (allowed to be repeated for once, the subject needs to be excluded if the two measurements of QTcF are > 450ms);
    11. Acute disease or concomitant medication from screening to prior to administration of study drug;
    12. Positive urine drug screen, or history of drug abuse or use of narcotics in the past 5 years;
    13. Positive in five hepatitis B markers at screening; or positive anti-HBc and negative anti-HBs; or positive antibody; or positive antibody; or positive Treponema pallidum antibody;
    14. Intake of any alcohol-containing product within 48 hours prior to dosing of study drug, or failure to limit alcohol consumption as required during the study;
    15. Currently or previously having malignant tumor;
    16. History of hypertension, or systolic blood pressure ≥ 140 mmHg, or diastolic blood pressure ≥90 mmHg at screening/baseline (allowed to be repeated for once, the subject needs to be excluded if the two measurements of systolic blood pressure ≥ 140 mmHg, or diastolic blood pressure ≥90 mmHg);
    17. Patients with hepatic disorder who are judged by investigators as inappropriate for enrollment;
    18. Presence of active infection, including acute and chronic infection as well as local infection;
    19. Chest X-ray showing active pulmonary tuberculosis; or previous history of tuberculosis or latent tuberculosis infection, or clinical manifestations suspected as tuberculosis (including but not limited to pulmonary tuberculosis); Positive for T-SPOT®.TB interferon-γ-release assays, or contact with patients with tuberculosis within three months or/and symptoms or/and signs suspected as tuberculosis;
    20. Had received or plan to receive or within 12 weeks prior to administration of study drug;
    21. Having participated in drug clinical trial within three months prior to the first dose of study drug, or plan to participate in other drug clinical trial during the study;
    22. Those who are considered by investigators as inappropriate for enrollment.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    BAT1806 prefilled subcutaneous injection

    Drug: BAT1806 prefilled subcutaneous injection/RoActemra® (from EU)

  • Active comparator
    RoActemra® (from EU)

    Drug: BAT1806 prefilled subcutaneous injection/RoActemra® (from EU)

Interventions

  • DrugBAT1806 prefilled subcutaneous injection/RoActemra® (from EU)

    Drug page: Tocilizumab

    A total of 150 subjects are planned to be enrolled and 1:1randomized to receive single dose of 162 mg/0.9 mL BAT1806 injection, or RoActemra® (from EU) subcutaneously.

06

What researchers measure

Primary outcomes

  1. AUC0-inf

    Time frame: from Day0 to Day57

  2. AUC0-t

    Time frame: from Day0 to Day57

  3. Cmax

    Time frame: from Day0 to Day57

07

Study locations

1 site
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Oct 2024, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2023
First posted
Aug 1, 2023
StartActual
Aug 29, 2023
Primary completionActual
Oct 8, 2024
CompletionActual
Oct 8, 2024
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05968508
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Aug 29, 2023
Primary completion
Oct 8, 2024
Completion
Oct 8, 2024
Last update
May 29, 2025

Study contacts

Wei Hu, Ph.D
principal investigator · The Second Hospital of Anhui Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion